SCHEDULE: Vanguard Group Divests ADMA Biologics Stake

The Vanguard Group reports 0% beneficial ownership in ADMA Biologics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in ADMA Biologics Inc.
• As of March 13, 2026, The Vanguard Group reports 0% beneficial ownership of ADMA Biologics Inc. common stock.
• This change is due to an internal realignment on January 12, 2026, where certain subsidiaries and business divisions will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated entities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development for ADMA Biologics Inc. as a major institutional entity no longer reports a direct stake, despite the reason being an internal realignment within Vanguard.

Positives

• The filing clarifies The Vanguard Group's current ownership structure and beneficial ownership, indicating transparency.
• The internal realignment allows for more granular reporting by subsidiaries, potentially improving transparency for specific funds.

Negatives

• The Vanguard Group, as the primary reporting entity, no longer holds a direct stake in ADMA Biologics Inc., which could be interpreted as a lack of institutional interest from this specific entity.

Risks

• A significant institutional investor (The Vanguard Group, as a single entity) no longer holding a stake could be perceived negatively by the market, potentially impacting investor sentiment for ADMA Biologics Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance for ADMA Biologics Inc. It solely reports a change in beneficial ownership for The Vanguard Group.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major asset managers like Vanguard, are closely watched by the market. While this filing indicates a structural change within Vanguard rather than a direct investment decision against ADMA Biologics, the disaggregation means that The Vanguard Group, as a single reporting entity, no longer holds a stake. This could lead to a perception of reduced institutional interest, even if the underlying funds still hold shares through different reporting entities.

Comparison to Industry Standards

• This filing is a standard Schedule 13G/A, which is a common regulatory disclosure for institutional investors.
• The internal realignment by The Vanguard Group is a specific organizational change, not directly comparable to ADMA Biologics' operational performance or industry benchmarks.
• The 0% ownership by The Vanguard Group (as the reporting entity) means it no longer meets the threshold for significant beneficial ownership, unlike other major institutional holders who might maintain stakes above 5% in similar biotech companies.

Stakeholder Impact

• Shareholders: May perceive a reduction in institutional interest, potentially impacting stock price or sentiment.
• Investment Professionals: Will need to track beneficial ownership from Vanguard's disaggregated entities for a complete picture.

Key Dates

Recommendation

The filing indicates that The Vanguard Group, as the primary reporting entity, has divested its entire beneficial ownership in ADMA Biologics Inc. While this is attributed to an internal realignment within Vanguard, the market often interprets a major institutional investor's complete exit as a negative signal, regardless of the underlying reason. This could lead to downward pressure on the stock price due to perceived reduced institutional confidence or liquidity. Investors might consider selling to mitigate potential negative sentiment.

Keywords

ADMA Biologics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Investment Adviser, Ownership Change